Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 2.8% – Here’s Why

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) dropped 2.8% on Monday . The stock traded as low as $1.66 and last traded at $1.72. Approximately 62,549 shares changed hands during trading, a decline of 22% from the average daily volume of 80,333 shares. The stock had previously closed at $1.77.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH increased their price target on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Stock Performance

The company’s 50 day moving average is $2.95 and its 200 day moving average is $3.28.

Insider Transactions at Marker Therapeutics

In other Marker Therapeutics news, Director Steve Elms bought 11,085 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the purchase, the director now owns 325,370 shares of the company’s stock, valued at approximately $1,041,184. This represents a 3.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of Marker Therapeutics stock in a transaction on Monday, December 23rd. The shares were bought at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the purchase, the insider now owns 1,625,678 shares in the company, valued at $5,202,169.60. The trade was a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 17.35% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Marker Therapeutics stock. Invst LLC bought a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned approximately 0.22% of Marker Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.